Research
Cellular
GLP-1 agonists influence various obesity-related processes including food intake regulation, insulin resistance, and inflammation.
Understanding these mechanisms can help practitioners tailor obesity treatments more effectively.
StrongSupportsmedium confidence
GLP-1 agonists affect diverse obesity etiopathogenic processes such as abnormal food intake regulation, adipocyte dysfunction, insulin resistance, adipokine production, inflammation, endothelial dysfunction, lipid metabolism, and oxidative stress.
Why this rating
The claim is based on established mechanisms of GLP-1 action as described in the abstract.
Source
GLP-1-based medications: Mechanisms involved in obesity treatment
Javier Salvador · Medicina Clínica (English Edition) · 2025
DOI 10.1016/j.medcle.2025.107035
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →